La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Galera Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Galera Therapeutics..

Galera Therapeutics (OTC:GRTX) Azioni, Catena delle Opzioni

Galera Therapeutics

Galera Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. The Firm's lead product candidate, avasopasem manganese, is a highly selective small molecule dismutase mimetic for severe oral mucositis (SOM) in patients with head and neck cancer (HNC), the reduction of esophagitis in patients with lung cancer, and the reduction of cisplatin-induced kidney damage in patients with cancer. The Firm's second product candidate, rucosopasem manganese, has been in development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC).

GALERA THERAPEUTICS INC by Galera Therapeutics, Inc.

Galera Therapeutics Inc

<p>Barclays  analyst Julian Mitchell   maintains Gates Industrial Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTES#NYSE">GTES</a>) with a Equal-Weight and raises the price target from $16 to $21.</p>


News

Price Target

Analyst Ratings

GTES

Barclays Maintains Equal-Weight on Gates Industrial Corp, Raises Price Target to $21

<p>Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Gilead Sciences to report an <strong>earnings per share</strong> (EPS) of $1.55.</p>
<p>Gilead Sciences bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS beat by $0.41, leading to a 2.55% drop in the share price on the subsequent day.</p>
<p>Here's a look at Gilead Sciences's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.60</td>
<td>-1.49</td>
<td>1.78</td>
<td>1.92</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.01</td>
<td>-1.32</td>
<td>1.72</td>
<td>2.29</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-3.0%</td>
<td>0.0%</td>
<td>-4.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730815412_0.png" alt="eps graph" /></p>
<h3>Performance of Gilead Sciences Shares</h3>
<p>Shares of Gilead Sciences were trading at $89.84 as of November 04. Over the last 52-week period, shares are up 15.33%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Views on Gilead Sciences</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Gilead Sciences.</p>
<p>The consensus rating for Gilead Sciences is Neutral, based on 16 analyst ratings. With an average one-year price target of $84.25, there's a potential 6.22% downside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Vertex Pharmaceuticals, Regeneron Pharmaceuticals and Amgen, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>The prevailing sentiment among analysts is an Neutral trajectory for Vertex Pharmaceuticals, with an average 1-year price target of $495.09, implying a potential 451.08% upside.</li>
<li>The consensus outlook from analysts is an Outperform trajectory for Regeneron Pharmaceuticals, with an average 1-year price target of $1172.19, indicating a potential 1204.75% upside.</li>
<li>The prevailing sentiment among analysts is an Neutral trajectory for Amgen, with an average 1-year price target of $347.8, implying a potential 287.13% upside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
<p>The peer analysis summary presents essential metrics for Vertex Pharmaceuticals, Regeneron Pharmaceuticals and Amgen, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gilead Sciences</td>
<td>Neutral</td>
<td>5.36%</td>
<td>$5.41B</td>
<td>9.01%</td>
</tr>
<tr>
<td>Vertex Pharmaceuticals</td>
<td>Neutral</td>
<td>6.11%</td>
<td>$2.27B</td>
<td>-21.57%</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals</td>
<td>Outperform</td>
<td>10.65%</td>
<td>$3.23B</td>
<td>4.66%</td>
</tr>
<tr>
<td>Amgen</td>
<td>Neutral</td>
<td>23.18%</td>
<td>$5.19B</td>
<td>42.08%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Gilead Sciences ranks in the middle for revenue growth among its peers. It has the highest gross profit margin. The company's return on equity is higher than two peers and lower than one. Overall, Gilead Sciences is positioned competitively within its peer group based on these metrics.</p>
<h3>Delving into Gilead Sciences's Background</h3>
<p>Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).</p>
<h3>Gilead Sciences: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Gilead Sciences showcased positive performance, achieving a revenue growth rate of <strong>5.36%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Gilead Sciences's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>23.21%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Gilead Sciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>9.01%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Gilead Sciences's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>2.94%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.28</strong>.</p>
<p><a href="https://www.benzinga.com/quote/GILD/earnings"><strong>To track all earnings releases for Gilead Sciences visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

GILD

Gilead Sciences's Earnings: A Preview

BLNK

Blink Charging Establishes £100M Special Purpose Vehicle For EV Charger Expansion, Partnering With Axxeltrova Capital To Drive Infrastructure Growth And Attract Sustainable Investment

<p><strong>Sun Communities</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUI#NYSE">SUI</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-11-06. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Sun Communities will report an <strong>earnings per share</strong> (EPS) of $2.52. </p>
<p>The market awaits Sun Communities's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Performance in Previous Earnings</h3>
<p>The company's EPS missed by $0.02 in the last quarter, leading to a 5.11% increase in the share price on the following day.</p>
<p>Here's a look at Sun Communities's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.88</td>
<td>1.16</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.86</td>
<td>1.19</td>
<td>1.34</td>
<td>2.57</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>5.0%</td>
<td>-7.000000000000001%</td>
<td>2.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Stock Performance</h3>
<p>Shares of Sun Communities were trading at $130.28 as of November 04. Over the last 52-week period, shares are up 11.3%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Views on Sun Communities</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Sun Communities.</p>
<p>The consensus rating for Sun Communities is Neutral, derived from 7 analyst ratings. An average one-year price target of $148.57 implies a potential 14.04% upside.</p>
<h3>Peer Ratings Comparison</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Equity Lifestyle Props, American Homes 4 Rent and Invitation Homes, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>The prevailing sentiment among analysts is an Neutral trajectory for Equity Lifestyle Props, with an average 1-year price target of $75.0, implying a potential 42.43% downside.</li>
<li>For American Homes 4 Rent, analysts project an Neutral trajectory, with an average 1-year price target of $42.11, indicating a potential 67.68% downside.</li>
<li>Invitation Homes received a Neutral consensus from analysts, with an average 1-year price target of $38.17, implying a potential 70.7% downside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>The peer analysis summary outlines pivotal metrics for Equity Lifestyle Props, American Homes 4 Rent and Invitation Homes, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sun Communities</td>
<td>Neutral</td>
<td>1.09%</td>
<td>$395.90M</td>
<td>0.75%</td>
</tr>
<tr>
<td>Equity Lifestyle Props</td>
<td>Neutral</td>
<td>-0.64%</td>
<td>$174.24M</td>
<td>5.78%</td>
</tr>
<tr>
<td>American Homes 4 Rent</td>
<td>Neutral</td>
<td>5.54%</td>
<td>$241.05M</td>
<td>1.05%</td>
</tr>
<tr>
<td>Invitation Homes</td>
<td>Neutral</td>
<td>6.90%</td>
<td>$383.71M</td>
<td>0.95%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Sun Communities is positioned in the middle among its peers for revenue growth. It ranks at the bottom for gross profit and return on equity.</p>
<h3>All You Need to Know About Sun Communities</h3>
<p>Sun Communities is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently owns a portfolio of 666 properties, which includes 350 manufactured housing communities, 179 residential vehicle communities, and 137 marina properties. Sun targets owning properties that are desirable as second homes or vacation properties with nearly 50% of the portfolio located in either Florida or Michigan near major bodies of water.</p>
<h3>Financial Insights: Sun Communities</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Sun Communities's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately <strong>1.09%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Real Estate sector.</p>
<p><strong>Net Margin:</strong> Sun Communities's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>6.03%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Sun Communities's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>0.75%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.3%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.14</strong>.</p>
<p><a href="https://www.benzinga.com/quote/SUI/earnings"><strong>To track all earnings releases for Sun Communities visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


What to Expect from Sun Communities's Earnings

Contracts

TTEK

Tetra Tech Announced That The Defense Logistics Agency Selected The Company For Its $12B J6 Enterprise Technology Services Award Contract

<p>GFL Environmental (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>) is preparing to release its quarterly earnings on Wednesday, 2024-11-06. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect GFL Environmental to report an <strong>earnings per share</strong> (EPS) of $0.25.</p>
<p>Investors in GFL Environmental are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Overview of Past Earnings</h3>
<p>In the previous earnings release, the company missed EPS by $0.01, leading to a 3.32% increase in the share price the following trading session.</p>
<p>Here's a look at GFL Environmental's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.22</td>
<td>-0.02</td>
<td>0.23</td>
<td>0.22</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.21</td>
<td>0</td>
<td>0.04</td>
<td>0.24</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>3.0%</td>
<td>5.0%</td>
<td>-3.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730815392_0_0.png" alt="eps graph" /></p>
<h3>Market Performance of GFL Environmental's Stock</h3>
<p>Shares of GFL Environmental were trading at $41.36 as of November 01. Over the last 52-week period, shares are up 43.81%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/GFL/earnings"><strong>To track all earnings releases for GFL Environmental visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Preview: GFL Environmental's Earnings

<p>Ratings for Lithia Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAD#NYSE">LAD</a>) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $353.5, a high estimate of $405.00, and a low estimate of $299.00. This upward trend is evident, with the current average reflecting a 12.85% increase from the previous average price target of $313.25.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730815385_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Lithia Motors. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rajat Gupta</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$405.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>Ali Faghri</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$380.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Jeff Lick</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$405.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Colin Langan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$343.00</td>
<td>$299.00</td>
</tr>
<tr>
<td>Colin Langan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$299.00</td>
<td>$302.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$320.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Adam Jonas</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$310.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Jeff Lick</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Overweight</td>
<td>$360.00</td>
<td>-</td>
</tr>
<tr>
<td>Rajat Gupta</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$375.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Ali Faghri</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$338.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Lithia Motors. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Lithia Motors compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Lithia Motors's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Lithia Motors's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LAD/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Lithia Motors analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Lithia Motors</h2>
<p>Lithia Motors is a retailer of new and used vehicles and related services. The company offers over 50 brands of vehicles at nearly 500 stores globally across the US, Canada, and UK. The company has expanded largely through the acquisition of dealerships in smaller regional markets but now seeks to grow in any part of the US and we expect more deals over time in the US and, at times, abroad. Annual revenue in 2023 was $31 billion and we see over $50 billion possible in a few years. The US was 90% of 2023 revenue and the UK second at 6%, the latter should rise to around 20% with the 2024 Pendragon acquisition. In 2023, new-car sales were about 49% of total revenue. Lithia was founded in 1946, went public in 1996, and is the largest US auto dealer. It is based in Medford, Oregon.</p>
<h3>Breaking Down Lithia Motors's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Growth:</strong> Lithia Motors's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>11.41%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>2.27%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Lithia Motors's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>3.22%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Lithia Motors's ROA excels beyond industry benchmarks, reaching <strong>0.9%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Lithia Motors's debt-to-equity ratio is below the industry average at <strong>2.13</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Critical Insights From Lithia Motors Analyst Ratings: What You Need To Know

<p>Genmab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMAB#NASDAQ">GMAB</a>) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Genmab to report an <strong>earnings per share</strong> (EPS) of $0.35.</p>
<p>The market awaits Genmab's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS missed by $0.02, leading to a 2.36% drop in the share price on the subsequent day.</p>
<p>Here's a look at Genmab's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.33</td>
<td>0.14</td>
<td>4.02</td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.31</td>
<td>0.29</td>
<td>0.36</td>
<td>0.47</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>7.000000000000001%</td>
<td>2.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Market Performance of Genmab's Stock</h3>
<p>Shares of Genmab were trading at $22.78 as of November 04. Over the last 52-week period, shares are down 26.52%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Views on Genmab</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Genmab.</p>
<p>A total of 10 analyst ratings have been received for Genmab, with the consensus rating being Buy. The average one-year price target stands at $46.2, suggesting a potential 102.81% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of Incyte, Natera and Exact Sciences, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>The consensus outlook from analysts is an Neutral trajectory for Incyte, with an average 1-year price target of $72.88, indicating a potential 219.93% upside.</li>
<li>The prevailing sentiment among analysts is an Outperform trajectory for Natera, with an average 1-year price target of $140.15, implying a potential 515.23% upside.</li>
<li>The consensus outlook from analysts is an Outperform trajectory for Exact Sciences, with an average 1-year price target of $83.33, indicating a potential 265.8% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
<p>In the peer analysis summary, key metrics for Incyte, Natera and Exact Sciences are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genmab</td>
<td>Buy</td>
<td>29.58%</td>
<td>$5.21B</td>
<td>4.44%</td>
</tr>
<tr>
<td>Incyte</td>
<td>Neutral</td>
<td>23.81%</td>
<td>$1.05B</td>
<td>3.45%</td>
</tr>
<tr>
<td>Natera</td>
<td>Outperform</td>
<td>58.13%</td>
<td>$243.17M</td>
<td>-4.59%</td>
</tr>
<tr>
<td>Exact Sciences</td>
<td>Outperform</td>
<td>12.41%</td>
<td>$509.46M</td>
<td>-0.50%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Genmab ranks at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity.</p>
<h3>Unveiling the Story Behind Genmab</h3>
<p>Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson &amp; Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson &amp; Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.</p>
<h3>Key Indicators: Genmab's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Genmab displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>29.58%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Genmab's net margin excels beyond industry benchmarks, reaching <strong>26.06%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>4.44%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Genmab's ROA excels beyond industry benchmarks, reaching <strong>3.74%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.03</strong>, Genmab adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/GMAB/earnings"><strong>To track all earnings releases for Genmab visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


GMAB

Preview: Genmab's Earnings

<p>Analysts' ratings for Group 1 Automotive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPI#NYSE">GPI</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $390.8, along with a high estimate of $430.00 and a low estimate of $285.00. Witnessing a positive shift, the current average has risen by 17.98% from the previous average price target of $331.25.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730815377_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The standing of Group 1 Automotive among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rajat Gupta</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$425.00</td>
<td>$420.00</td>
</tr>
<tr>
<td>Adam Jonas</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$430.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Jeff Lick</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$394.00</td>
<td>-</td>
</tr>
<tr>
<td>Rajat Gupta</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$420.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Adam Jonas</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$285.00</td>
<td>$260.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Group 1 Automotive. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Group 1 Automotive compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Group 1 Automotive's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Group 1 Automotive's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/GPI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Group 1 Automotive analyst ratings.</strong></a></p>
<h2>About Group 1 Automotive</h2>
<p>As of October, Group 1 owns and operates 44 collision centers and 260 automotive dealerships in the US and the UK, offering 35 brands of automobiles altogether. About 150 of the stores are in the US with locations mostly in metropolitan areas in 17 states in the Northeast, Southeast, Midwest, and California. Texas alone contributed 38% of new-vehicle unit volume in 2023 and the UK about 19%. Texas, Oklahoma, and Massachusetts combined was 53%. Revenue in 2023 totaled $17.9 billion. The August, Inchcape UK deal adds about $2.7 billion of annual revenue and 54 stores to bring the UK store count to 114. Group 1 was founded in 1995 and is based in Houston.</p>
<h3>Group 1 Automotive's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Group 1 Automotive's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>10.97%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Group 1 Automotive's net margin excels beyond industry benchmarks, reaching <strong>2.2%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>3.93%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Group 1 Automotive's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.22%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Group 1 Automotive's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>1.84</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Assessing Group 1 Automotive: Insights From 5 Financial Analysts

<p>As part of its aggressive actions to improve the performance of the Bombshells segment, RCI Hospitality Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RICK#NASDAQ">RICK</a>) announced the decision to permanently close two underperforming leased locations and sell a third. The company said that Bombshells Spring at 21005 Interstate 45 N, Spring, TX, and Bombshells Houston-South at 12810 Gulf Freeway, Houston, TX have been closed and that there are plans to sell Bombshells Austin at 15119 N Interstate Hwy 35, Pflugerville, TX. RCI said it will disclose related financial details when it reports fourth quarter and year end results which are expected by December 16, 2024.</p>


RICK

RCI Announces The Decision To Permanently Close Two Underperforming Leased Locations And Sell A Third Underperforming Bombshells; No Financial Terms Disclosed

<p>Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) is preparing to release its quarterly earnings on Wednesday, 2024-11-06. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Royalty Pharma to report an <strong>earnings per share</strong> (EPS) of $0.93.</p>
<p>Investors in Royalty Pharma are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings Track Record</h3>
<p>During the last quarter, the company reported an EPS missed by $0.03, leading to a 0.42% increase in the share price on the subsequent day.</p>
<p>Here's a look at Royalty Pharma's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.99</td>
<td>0.99</td>
<td>0.99</td>
<td>0.77</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.96</td>
<td>0.98</td>
<td>1.15</td>
<td>0.79</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>0.0%</td>
<td>0.0%</td>
<td>-0.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730815375_0.png" alt="eps graph" /></p>
<h3>Insights Shared by Analysts on Royalty Pharma</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Royalty Pharma.</p>
<p>With 2 analyst ratings, Royalty Pharma has a consensus rating of Buy. The average one-year price target is $45.5, indicating a potential 67.28% upside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Intra-Cellular Therapies, Jazz Pharmaceuticals and Elanco Animal Health, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Intra-Cellular Therapies received a Outperform consensus from analysts, with an average 1-year price target of $100.93, implying a potential 271.07% upside.</li>
<li>As per analysts' assessments, Jazz Pharmaceuticals is favoring an Outperform trajectory, with an average 1-year price target of $180.2, suggesting a potential 562.5% upside.</li>
<li>Elanco Animal Health is maintaining an Outperform status according to analysts, with an average 1-year price target of $19.0, indicating a potential 30.15% downside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
<p>Within the peer analysis summary, vital metrics for Intra-Cellular Therapies, Jazz Pharmaceuticals and Elanco Animal Health are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catalent</td>
<td>Neutral</td>
<td>23.32%</td>
<td>$384M</td>
<td>0.64%</td>
</tr>
<tr>
<td>Intra-Cellular Therapies</td>
<td>Outperform</td>
<td>39.23%</td>
<td>$159.85M</td>
<td>-2.30%</td>
</tr>
<tr>
<td>Jazz Pharmaceuticals</td>
<td>Outperform</td>
<td>6.95%</td>
<td>$913.92M</td>
<td>4.52%</td>
</tr>
<tr>
<td>Elanco Animal Health</td>
<td>Outperform</td>
<td>12.02%</td>
<td>$689M</td>
<td>-0.83%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Royalty Pharma ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.</p>
<h3>About Royalty Pharma</h3>
<p>Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson &amp; Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.</p>
<h3>Royalty Pharma: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Challenges:</strong> Royalty Pharma's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately <strong>-0.17%</strong>. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Royalty Pharma's net margin excels beyond industry benchmarks, reaching <strong>18.99%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>1.57%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Royalty Pharma's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.6%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.17</strong>.</p>
<p><a href="https://www.benzinga.com/quote/RPRX/earnings"><strong>To track all earnings releases for Royalty Pharma visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


RPRX

Insights Ahead: Royalty Pharma's Quarterly Earnings

WIIM

Trump Media & Technology Group shares are trading higher amid the US presidential election.

TSBX

Turnstone Biologics shares are trading higher after the company announced it will be presenting two posters highlighting preclinical data on methods for TIL selection at the STIC 39th Annual Meeting.

<p>Across the recent three months, 6 analysts have shared their insights on Chemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CC#NYSE">CC</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $25.33, with a high estimate of $32.00 and a low estimate of $21.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 8.98%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730815357_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Chemours. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$23.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$25.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Duffy Fischer</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Chemours. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Chemours compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Chemours's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Chemours's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Chemours analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Chemours</h2>
<p>The Chemours Co is a global provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal &amp; Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.</p>
<h3>Financial Insights: Chemours</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Challenges:</strong> Chemours's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately <strong>-6.39%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Materials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>4.55%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Chemours's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>9.49%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Chemours's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.92%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Chemours's debt-to-equity ratio is below the industry average at <strong>5.86</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What Analysts Are Saying About Chemours Stock

<p>Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) in the last three months.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $6.75, a high estimate of $8.00, and a low estimate of $6.00. Surpassing the previous average price target of $6.00, the current average has increased by 12.5%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730815348_0_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Geron. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emily Bodnar</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$8.00</td>
<td>-</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$6.00</td>
<td>-</td>
</tr>
<tr>
<td>Faisal Khurshid</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$7.00</td>
<td>-</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.00</td>
<td>$6.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Geron. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Geron compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Geron's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Geron's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/GERN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Geron analyst ratings.</strong></a></p>
<h2>Get to Know Geron Better</h2>
<p>Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.</p>
<h3>A Deep Dive into Geron's Financials</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Geron displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>2941.38%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Geron's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-7639.8%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Geron's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-20.68%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-14.47%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>0.28</strong>, Geron faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


GERN

Analyst Ratings For Geron

<p>American Electric Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate American Electric Power to report an <strong>earnings per share</strong> (EPS) of $1.80.</p>
<p>Anticipation surrounds American Electric Power's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings Track Record</h3>
<p>During the last quarter, the company reported an EPS beat by $0.02, leading to a 0.02% drop in the share price on the subsequent day.</p>
<p>Here's a look at American Electric Power's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.23</td>
<td>1.26</td>
<td>1.26</td>
<td>1.71</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.25</td>
<td>1.27</td>
<td>1.23</td>
<td>1.77</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-0.0%</td>
<td>2.0%</td>
<td>4.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730815348_0.png" alt="eps graph" /></p>
<h3>Performance of American Electric Power Shares</h3>
<p>Shares of American Electric Power were trading at $98.4 as of November 04. Over the last 52-week period, shares are up 25.91%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Views on American Electric Power</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding American Electric Power.</p>
<p>The consensus rating for American Electric Power is Outperform, based on 12 analyst ratings. With an average one-year price target of $106.75, there's a potential 8.49% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of PG&amp;E, Exelon and Xcel Energy, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>The consensus outlook from analysts is an Buy trajectory for PG&amp;E, with an average 1-year price target of $23.0, indicating a potential 76.63% downside.</li>
<li>For Exelon, analysts project an Neutral trajectory, with an average 1-year price target of $43.33, indicating a potential 55.97% downside.</li>
<li>The prevailing sentiment among analysts is an Neutral trajectory for Xcel Energy, with an average 1-year price target of $69.45, implying a potential 29.42% downside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>The peer analysis summary outlines pivotal metrics for PG&amp;E, Exelon and Xcel Energy, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>American Electric Power</td>
<td>Outperform</td>
<td>4.73%</td>
<td>$2.86B</td>
<td>1.31%</td>
</tr>
<tr>
<td>PG&amp;E</td>
<td>Buy</td>
<td>13.16%</td>
<td>$2.26B</td>
<td>2.00%</td>
</tr>
<tr>
<td>Exelon</td>
<td>Neutral</td>
<td>2.91%</td>
<td>$2.50B</td>
<td>2.68%</td>
</tr>
<tr>
<td>Xcel Energy</td>
<td>Neutral</td>
<td>-0.49%</td>
<td>$1.86B</td>
<td>3.66%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>American Electric Power ranks highest in revenue growth among its peers. It has the lowest gross profit and return on equity compared to its peers.</p>
<h3>Get to Know American Electric Power Better</h3>
<p>American Electric Power is one of the largest regulated utilities in the United States, providing electricity generation, transmission, and distribution to more than 5 million customers in 11 states. About 42% of AEP's of capacity is coal, with the remainder from a mix of natural gas (27%), renewable energy and hydro (21%), nuclear (8%), and demand response (2%). Vertically integrated utilities, transmission and distribution, and generation and marketing support earnings.</p>
<h3>Financial Insights: American Electric Power</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Positive Revenue Trend:</strong> Examining American Electric Power's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>4.73%</strong> as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Utilities sector.</p>
<p><strong>Net Margin:</strong> American Electric Power's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>7.43%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>1.31%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> American Electric Power's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.34%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> American Electric Power's debt-to-equity ratio surpasses industry norms, standing at <strong>1.7</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<p><a href="https://www.benzinga.com/quote/AEP/earnings"><strong>To track all earnings releases for American Electric Power visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Insights Ahead: American Electric Power's Quarterly Earnings

<p>Barclays  analyst Nicholas Campanella   maintains Entergy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>) with a Overweight and raises the price target from $137 to $152.</p>


Barclays Maintains Overweight on Entergy, Raises Price Target to $152

<p>Seanergy Maritime Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIP#NASDAQ">SHIP</a>) reported quarterly earnings of $0.69 per share which missed the analyst consensus estimate of $0.75 by 8 percent.  The company reported quarterly sales of $44.356 million which missed the analyst consensus estimate of $45.842 million by 3.24 percent.  This is a 81.40 percent increase over sales of $24.452 million the same period last year.</p>


Earnings Misses

SHIP

Seanergy Maritime Hldgs Q3 2024 Adj. EPS $0.69 Misses $0.75 Estimate, Sales $44.356M Miss $45.842M Estimate

Biotech

General

Turnstone Biologics Showcases Preclinical Data On Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy For Solid Tumors At SITC 2024, Supporting Clinical Advancement Of TIDAL-01 In Phase 1 Trials

<p>Western Midstream (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WES#NYSE">WES</a>) is gearing up to announce its quarterly earnings on Wednesday, 2024-11-06. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Western Midstream will report an <strong>earnings per share</strong> (EPS) of $0.83.</p>
<p>Investors in Western Midstream are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS beat by $0.09 in the last quarter, leading to a 1.13% increase in the share price on the following day.</p>
<p>Here's a look at Western Midstream's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.88</td>
<td>0.81</td>
<td></td>
<td>0.65</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.97</td>
<td>1.47</td>
<td>0.74</td>
<td>0.70</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>3.0%</td>
<td>11.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Performance of Western Midstream Shares</h3>
<p>Shares of Western Midstream were trading at $36.81 as of November 01. Over the last 52-week period, shares are up 34.1%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Opinions on Western Midstream</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Western Midstream.</p>
<p>Analysts have given Western Midstream a total of 6 ratings, with the consensus rating being Neutral. The average one-year price target is $40.0, indicating a potential 8.67% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Plains All American, DT Midstream and Antero Midstream, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>As per analysts' assessments, Plains All American is favoring an Neutral trajectory, with an average 1-year price target of $19.0, suggesting a potential 48.38% downside.</li>
<li>DT Midstream is maintaining an Neutral status according to analysts, with an average 1-year price target of $88.14, indicating a potential 139.45% upside.</li>
<li>The prevailing sentiment among analysts is an Underperform trajectory for Antero Midstream, with an average 1-year price target of $16.0, implying a potential 56.53% downside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>Within the peer analysis summary, vital metrics for Plains All American, DT Midstream and Antero Midstream are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Western Midstream</td>
<td>Neutral</td>
<td>22.67%</td>
<td>$688.19M</td>
<td>11.34%</td>
</tr>
<tr>
<td>Plains All American</td>
<td>Neutral</td>
<td>11.47%</td>
<td>$468M</td>
<td>1.75%</td>
</tr>
<tr>
<td>DT Midstream</td>
<td>Neutral</td>
<td>5.98%</td>
<td>$195M</td>
<td>2.09%</td>
</tr>
<tr>
<td>Antero Midstream</td>
<td>Underperform</td>
<td>2.14%</td>
<td>$185.61M</td>
<td>4.68%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Western Midstream ranks in the top quartile for Revenue Growth and Gross Profit among its peers. However, it ranks in the bottom quartile for Return on Equity.</p>
<h3>Unveiling the Story Behind Western Midstream</h3>
<p>Western Midstream Partners LP is a US-based company which own, operate, acquire and develop midstream energy assets. The company through its subsidiary is engaged in the business of gathering, processing, compressing, treating and transporting natural gas, condensate, NGLs and crude oil. It owns or has investments in assets located in the Rocky Mountains (Colorado, Utah, and Wyoming), the Mid-Continent (Kansas and Oklahoma), North-central Pennsylvania and Texas.</p>
<h3>Western Midstream: A Financial Overview</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Western Midstream's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>22.67%</strong> as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Energy sector.</p>
<p><strong>Net Margin:</strong> Western Midstream's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>40.84%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Western Midstream's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>11.34%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Western Midstream's ROA excels beyond industry benchmarks, reaching <strong>3.03%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Western Midstream's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>2.18</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<p><a href="https://www.benzinga.com/quote/WES/earnings"><strong>To track all earnings releases for Western Midstream visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Western Midstream's Earnings: A Preview

Galera Therapeutics GAAP EPS of -$0.10

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>It&rsquo;s time to dive into the biggest pre-market stock movers with all of the hottest news worth reading about on Wednesday!</p>



<p>Moving stocks this morning are earnings reports, acquisition plans, new drug data and more.</p>



<p>Let&rsquo;s get into that news below!</p>



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li><strong>INVO Bioscience</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/invo-stock-quote/"><strong>INVO</strong></a>) stock is rocketing more than 55% alongside its <a href="https://finance.yahoo.com/news/invo-reports-fourth-quarter-full-205900118.html">Q4 earnings report</a>.</li>



<li><strong>Vanda Pharmaceuticals </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/vnda-stock-quote/"><strong>VNDA</strong></a>) shares are soaring over 38% on <a href="https://www.nasdaq.com/press-release/future-pak-confirms-proposal-to-acquire-vanda-pharmaceuticals-for-%247.25-to-%247.75-per">a firm acquisition proposal</a>.</li>



<li><strong>VIA Optronics</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/viao-stock-quote/"><strong>VIAO</strong></a>) stock is surging more than 32% with heavy pre-market trading.</li>



<li><strong>Clene </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/clnn-stock-quote/"><strong>CLNN</strong></a>) shares are rising over 26% on <a href="https://seekingalpha.com/news/4090283-clene-stock-rallies-post-market-on-ms-drug-data?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain%7Csection%3Aon-the-move">new drug data</a>.</li>



<li><strong>Chromocell Therapeutics</strong> (NYSEMKT:<a href="https://investorplace.com/stock-quotes/chro-stock-quote/"><strong>CHRO</strong></a>) stock is gaining more than 26% on an update to a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318239123&amp;type=PDF&amp;symbol=CHRO&amp;cdn=722216dc7f57070dff83767fe9648f9d&amp;companyName=Chromocell+Therapeutics+Corporation&amp;formType=424B3&amp;formDescription=Prospectus+%5BRule+424%28b%29%283%29%5D&amp;dateFiled=2024-04-17">secondary stock offering</a>.</li>



<li><strong>CXApp </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/cxai-stock-quote/"><strong>CXAI</strong></a>) shares are increasing over 26% with its <a href="https://www.marketwatch.com/story/cxapp-shares-rise-29-on-4q-2023-annual-recurring-revenue-growth-13f8abea">latest earnings report</a>.</li>



<li><strong>Seelos Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/seel-stock-quote/"><strong>SEEL</strong></a>) stock is climbing more than 24% without any clear news on Wednesday morning.</li>



<li><strong>Mobile Global Esports</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/mgam-stock-quote/"><strong>MGAM</strong></a>) shares are getting a 22% boost as it <a href="https://investorplace.com/2024/04/why-is-mobile-global-esports-mgam-stock-down-18-today/">prepares for delisting</a>.</li>



<li><strong>Gamer Pakistan</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/gpak-stock-quote/"><strong>GPAK</strong></a>) stock is jumping 21% despite a lack of news today.</li>



<li><strong>Galera Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/grtx-stock-quote/"><strong>GRTX</strong></a>) shares are up over 19% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318238318&amp;type=PDF&amp;symbol=GRTX&amp;cdn=6788b7c94daccbdc9a6c5412e270d44c&amp;companyName=Galera+Therapeutics+Inc.&amp;formType=SC+13G&amp;formDescription=Statement+of+acquisition+of+beneficial+ownership+by+individuals&amp;dateFiled=2024-04-16">shareholder stake update</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li><strong>Trilogy Metals</strong> (NYSEMKT:<a href="https://investorplace.com/stock-quotes/tmq-stock-quote/"><strong>TMQ</strong></a>) stock is plummeting more than 22% <a href="https://www.nasdaq.com/press-release/trilogy-metals-provides-update-on-the-ambler-access-project-2024-04-17">following an update</a> to its Ambler Access Project.</li>



<li><strong>Trio Petroleum</strong> (NYSEMKT:<a href="https://investorplace.com/stock-quotes/tpet-stock-quote/"><strong>TPET</strong></a>) shares are diving over 20% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318239194&amp;type=PDF&amp;symbol=TPET&amp;cdn=fb7a5495a316777660288b1087458323&amp;companyName=Trio+Petroleum+Corp.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-17">securing senior notes and a purchase agreement</a>.</li>



<li><strong>Connexa Sports Technologies</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/yyai-stock-quote/"><strong>YYAI</strong></a>) stock is tumbling more than 18% on Wednesday morning.</li>



<li><strong>Destiny Tech100</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/dxyz-stock-quote/"><strong>DXYZ</strong></a>) shares are taking a close to 18% beating following a rally yesterday.</li>



<li><strong>Ontrak </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/otrk-stock-quote/"><strong>OTRK</strong></a>) stock is sliding over 16% with the release of its <a href="https://finance.yahoo.com/news/ontrak-announces-2023-fourth-quarter-200500612.html">Q4 2023 earnings report</a>.</li>



<li><strong>Dragonfly Energy</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/dfli-stock-quote/"><strong>DFLI</strong></a>) shares are retreating more than 16% <a href="https://investorplace.com/2024/04/why-is-dragonfly-energy-dfli-stock-up-56-today/">after rallying yesterday</a>.</li>



<li><strong>Dynatronics </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/dynt-stock-quote/"><strong>DYNT</strong></a>) stock is pulling back over 16% <a href="https://investorplace.com/2024/04/why-is-dynatronics-dynt-stock-up-93-today/">after rising on Tuesday</a>.</li>



<li><strong>Ryvyl </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/rvyl-stock-quote/"><strong>RVYL</strong></a>) shares are still falling more than 15% despite <a href="https://www.nasdaq.com/press-release/ryvyl-inc.-announces-cancellation-of-proposed-underwritten-public-offering-2024-04-16">canceling a proposed public offering</a>.</li>



<li><strong>Hub Cyber Security</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/hubc-stock-quote/"><strong>HUBC</strong></a>) stock is dropping over 14% <a href="https://investorplace.com/2024/04/why-is-hub-cyber-security-hubc-stock-up-35-today/">after a rally yesterday</a>.</li>



<li><strong>iSun </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/isun-stock-quote/"><strong>ISUN</strong></a>) shares close out our pre-market stock movers down more than 13% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318238741&amp;type=PDF&amp;symbol=ISUN&amp;cdn=82f25393dbc89b776256155c3f0856b7&amp;companyName=iSun+Inc.&amp;formType=10-K&amp;formDescription=Annual+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-16">on an investor update</a>.</li>
</ol><p><em>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-april-17th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>It&rsquo;s time to start off the trading week with a look at the biggest pre-market stock movers for Monday morning!</p>



<p>Moving stocks this morning are earnings, investments, a delisting and more.</p>



<p>Let&rsquo;s get into that news below!</p>



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li><strong>Moolec Science</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlec-stock-quote/"><strong>MLEC</strong></a>) stock is rocketing more than 67% on approval for its <a href="https://www.nasdaq.com/press-release/moolec-becomes-first-molecular-farming-company-to-achieve-usda-approval-for-plant">plant-groan animal proteins</a>.</li>



<li><strong>OLB Group</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/olb-stock-quote/"><strong>OLB</strong></a>) shares are soaring over 46% with heavy pre-market trading.</li>



<li><strong>Complete Solaria</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/cslr-stock-quote/"><strong>CSLR</strong></a>) stock is surging more than 42% <a href="https://www.nasdaq.com/press-release/retail-stock-sector-and-chairman-t.j.-rodgers-invest-in-complete-solaria-2024-04-21">on investment news</a>.</li>



<li><strong>SuperCom </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/spcb-stock-quote/"><strong>SPCB</strong></a>) shares are gaining over 33% ahead of its <a href="https://www.nasdaq.com/press-release/supercom-to-report-fourth-quarter-and-full-year-2023-financial-results-on-april-22">Q4 2023 earnings report</a> this morning.</li>



<li><strong>Dermata Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/"><strong>DRMA</strong></a>) stock is rising more than 18% on Monday morning.</li>



<li><strong>Galera Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/grtx-stock-quote/"><strong>GRTX</strong></a>) shares are increasing over 17% without any clear news this morning.</li>



<li><strong>Palisade Bio</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/pali-stock-quote/"><strong>PALI</strong></a>) stock is climbing more than 16% despite a lack of news today.</li>



<li><strong>Global Gas</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/hgas-stock-quote/"><strong>HGAS</strong></a>) shares are heading over 14% higher on Monday.</li>



<li><strong>Volato</strong> (NYSEMKT:<a href="https://investorplace.com/stock-quotes/soar-stock-quote/"><strong>SOAR</strong></a>) stock is jumping more than 13% on Monday morning.</li>



<li><strong>Portage Biotech</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/prtg-stock-quote/"><strong>PRTG</strong></a>) shares are up over 13% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li><strong>Vaxxinity </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/vaxx-stock-quote/"><strong>VAXX</strong></a>) stock is crashing more than 55% on the company&rsquo;s <a href="https://finance.yahoo.com/news/vaxxinity-announces-intention-voluntarily-delist-202700884.html">plans to delist its shares</a>.</li>



<li><strong>EzFill </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/ezfl-stock-quote/"><strong>EZFL</strong></a>) shares are plummeting close to 37% this morning.</li>



<li><strong>Hepion Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/hepa-stock-quote/"><strong>HEPA</strong></a>) stock is diving over 29% on plans to <a href="https://www.nasdaq.com/press-release/hepion-pharmaceuticals-initiates-wind-down-activities-in-phase-2b-ascend-nash-trial">wind down a clinical trial</a>.</li>



<li><strong>iLearningEngines</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/aile-stock-quote/"><strong>AILE</strong></a>) shares are tumbling more than 21% after <a href="https://finance.yahoo.com/news/ilearningengines-inc-becomes-publicly-traded-200500132.html">going public last week</a>.</li>



<li><strong>Redwoods Acquisition</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/rwod-stock-quote/"><strong>RWOD</strong></a>) stock is taking an over 15% beating <a href="https://investorplace.com/2024/04/why-is-redwoods-acquisition-rwod-stock-up-72-today/">after a recent rally</a>.</li>



<li><strong>Biophytis </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/bpts-stock-quote/"><strong>BPTS</strong></a>) shares are sliding more than 15% ahead of <a href="https://www.nasdaq.com/press-release/biophytis-announces-ratio-change-under-its-american-depositary-receipt-adr-program-0">a ratio change tomorrow</a>.</li>



<li><strong>Adlai Nortye</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/anl-stock-quote/"><strong>ANL</strong></a>) stock is dropping nearly 15% today.</li>



<li><strong>BioSig Technologies</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/bsgm-stock-quote/"><strong>BSGM</strong></a>) shares are falling over 13% this morning.</li>



<li><strong>Sunshine Biopharma</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/sbfm-stock-quote/"><strong>SBFM</strong></a>) stock is decreasing more than 12% today.</li>



<li><strong>Indonesia Energy</strong> (NYSEMKT:<a href="https://investorplace.com/stock-quotes/indo-stock-quote/"><strong>INDO</strong></a>) shares close out our pre-market stock movers down over 10%.</li>
</ol><p><em>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-april-22nd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Galera Therapeutics (GRTX) has issued an update. Galera Therapeutics, Inc. has implemented a stockholder rights plan, issuing one Right per common ...

Galera Therapeutics Enacts Plan to Deter Hostile Takeovers

Galera Therapeutics GAAP EPS of -$0.08

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Galera Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/grtx-stock-quote/"><strong>GRTX</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Galera Therapeutics reported earnings per share of -8 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/grtx-stock-earnings-galera-therapeutics-for-q1-of-2024/">GRTX Stock Earnings: Galera Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

GRTX Stock Earnings: Galera Therapeutics Reported Results for Q1 2024

Galera Therapeutics (GRTX) has provided an update. Galera Therapeutics, Inc. is streamlining its operations amidst a strategic review by eliminatin...

Galera Therapeutics Restructures Leadership and Cuts Costs

Galera Therapeutics (GRTX) just unveiled an announcement. Galera Therapeutics, Inc. recently settled a lawsuit against two Clinical Research Organi...

Galera Therapeutics Settles Clinical Trial Dispute Lawsuit

Galera Therapeutics (GRTX) has shared an update. Galera is set to dissolve and wind up its business, a decision made by the Board to benefit the sh...

Galera Therapeutics Announces Wind-Up and Special Stockholder Meeting

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Galera Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/grtx-stock-quote/"><strong>GRTX</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Galera Therapeutics reported earnings per share of -7 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/grtx-stock-earnings-galera-therapeutics-for-q2-of-2024/">GRTX Stock Earnings: Galera Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Comments

Galera Therapeutics

Galera Therapeutics (GRTX) Opzioni

Galera Therapeutics (OTC:GRTX) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO